Last reviewed · How we verify
NCT00790049
A Safety Study of ARRY-371797 in Healthy Subjects
Phase 1 trial testing ARRY-371797, p38 inhibitor; oral in Healthy in 40 participants. Completed in 21 January 2009.
21 January 2009
Quick facts
| Lead sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 31 October 2008 |
| Primary completion | 21 January 2009 |
| Estimated completion | 21 January 2009 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ARRY-371797, p38 inhibitor; oral
- Placebo; oral
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer — full company profile →
Who can join
Adults 18 to 60, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1 study, involving both 1-day and 8-day dosing periods, designed to test the safety of investigational study drug ARRY-371797 in healthy subjects. Approximately 48 healthy subjects from the US will be enrolled in this study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling.
Han J, Wu J, Silke J. · · 2020 · cited 103× · PMID 32612808 · DOI 10.12688/f1000research.22092.1
Verify or expand the search:
- PubMed search for NCT00790049
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ARRY-371797, p38 inhibitor; oral
Trials testing the same drug.
- NCT00811499 — A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis · Phase 2 · terminated
- NCT00663767 — A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction · Phase 2 · completed
- NCT00542035 — A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction · Phase 2 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00790049 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Array Biopharma, now a wholly owned subsidiary of Pfizer
- Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00790049.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing